FGF-21 (Fibroblast Growth Factor 21) is a hormone primarily produced by the liver, playing a crucial role in regulating metabolism, particularly of glucose and lipids. It acts as an endocrine factor that affects various tissues, including adipose tissue, liver, pancreas, and brain, to maintain metabolic homeostasis. FGF-21 Analogs are synthetic peptides designed to mimic or enhance the action of naturally occurring FGF-21. These analogs are being investigated for their therapeutic potential in treating metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). By stimulating similar pathways to endogenous FGF-21, these analogs aim to improve insulin sensitivity, reduce blood glucose levels, promote weight loss, and mitigate hepatic steatosis. Due to its significant effects on metabolic health, FGF-21 and its analogs are also of interest in the context of healthy aging and longevity. As a peptide, FGF-21 Analog is typically administered via injection, reflecting its biological nature and the need to bypass gastrointestinal degradation. (Source: PubChem, DrugBank)
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem (National Library of Medicine)", "DrugBank", "MedlinePlus (National Library of Medicine)", "ClinicalTrials.gov", "PubMed (National Library of Medicine)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.